Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Eupraxia Pharmaceuticals Inc (EPRX)

Eupraxia Pharmaceuticals Inc (EPRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 237,343
  • Shares Outstanding, K 35,961
  • Annual Sales, $ 0 K
  • Annual Income, $ -25,500 K
  • EBIT $ -30 M
  • EBITDA $ -30 M
  • 60-Month Beta 1.47
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.95

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.13
  • Number of Estimates 2
  • High Estimate -0.10
  • Low Estimate -0.15
  • Prior Year -0.21
  • Growth Rate Est. (year over year) +38.10%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.25 +25.71%
on 11/06/25
6.74 -2.08%
on 11/12/25
+0.53 (+8.73%)
since 10/10/25
3-Month
5.04 +30.95%
on 08/25/25
7.19 -8.21%
on 09/22/25
+1.23 (+22.82%)
since 08/12/25
52-Week
2.68 +146.26%
on 04/07/25
7.19 -8.21%
on 09/22/25
+3.70 (+127.79%)
since 11/12/24

Most Recent Stories

More News
Eupraxia Pharmaceuticals Reports Third Quarter 2025 Financial Results

Durable symptom and tissue responses observed out to 52 weeks following a single treatment with EP-104GI Enrollment continues in Phase 2b portion of the RESOLVE Trial, with topline data expected by...

EPRX : 6.60 (+1.07%)
EPRX.TO : 9.35 (+0.75%)
Eupraxia Pharmaceuticals Announces Positive Data from Highest-Dose Cohort in the Ongoing RESOLVE Trial in Eosinophilic Esophagitis, and Plans for Expansion of EP-104GI Development Programs

Clinical data was reported for the first time in patients receiving an 8 mg dose per injection (Cohort 9 of the dose escalation portion of RESOLVE), the highest dose planned in this trial. Patients...

EPRX : 6.60 (+1.07%)
EPRX.TO : 9.35 (+0.75%)
Eupraxia Pharmaceuticals Announces Closing of US$80.5 Million Public Offering Including Full Exercise of Underwriter Option

VICTORIA, British Columbia, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging...

EPRX : 6.60 (+1.07%)
EPRX.TO : 9.35 (+0.75%)
Eupraxia Pharmaceuticals Announces Pricing of US$70 Million Public Offering of Common Shares

VICTORIA, British Columbia, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging...

EPRX : 6.60 (+1.07%)
EPRX.TO : 9.35 (+0.75%)
Eupraxia Pharmaceuticals Announces Proposed Public Offering of Common Shares

VICTORIA, British Columbia, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging...

EPRX : 6.60 (+1.07%)
EPRX.TO : 9.35 (+0.75%)
First Set of 1-Year Clinical Results from RESOLVE Trial in Eosinophilic Esophagitis (EoE), Durable and Sustained Symptom & Tissue Responses after Dosing with EP-104GI

At 12 months, 2/3rds of Cohort 5 patients (48mg dose, 4mg per site) remained in clinical remission after their treatment with EP-104GI All Cohorts followed to 9 months have maintained clinically meaningful...

EPRX : 6.60 (+1.07%)
EPRX.TO : 9.35 (+0.75%)
Eupraxia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Announced first patient dosed in the Phase 2b placebo-controlled portion of the EP-104GI RESOLVE trial with topline data expected in H2 2026 Announced positive data from Phase 1b/2a RESOLVE supporting...

EPRX : 6.60 (+1.07%)
EPRX.TO : 9.35 (+0.75%)
Eupraxia Pharmaceuticals Invited to Present at Upcoming Investor Conferences

VICTORIA, British Columbia, July 22, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging...

EPRX : 6.60 (+1.07%)
EPRX.TO : 9.35 (+0.75%)
Eupraxia Doses First Patient in Phase 2b Placebo-Controlled Portion of EP-104GI RESOLVE Trial in Eosinophilic Esophagitis

EPRX : 6.60 (+1.07%)
EPRX.TO : 9.35 (+0.75%)
Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders

EPRX : 6.60 (+1.07%)
EPRX.TO : 9.35 (+0.75%)

Business Summary

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment...

See More

Key Turning Points

3rd Resistance Point 7.01
2nd Resistance Point 6.87
1st Resistance Point 6.74
Last Price 6.60
1st Support Level 6.47
2nd Support Level 6.33
3rd Support Level 6.20

See More

52-Week High 7.19
Last Price 6.60
Fibonacci 61.8% 5.47
Fibonacci 50% 4.94
Fibonacci 38.2% 4.40
52-Week Low 2.68

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar